⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1286786 | 0.77 | — | — | |
| SCHEMBL9257748 | 0.74 | — | — | |
| SCHEMBL7482527 | 0.74 | — | — | |
| SCHEMBL5063494 | 0.74 | — | — | |
| SCHEMBL16792097 | 0.72 | ENO1 (0.56) | — | |
| Lithium Ion SCHEMBL28856344 | 0.72 | ENO1 (0.56) | — | |
| SCHEMBL28724108 | 0.72 | ENO1 (0.56) | — | |
| SCHEMBL8446275 | 0.70 | ENO1 (0.54) | — | |
| SCHEMBL5063490 | 0.70 | ENO1 (0.54) | — | |
| SCHEMBL28916777 | 0.69 | ENO1 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250017950-A1 | COMPOUNDS FOR TREATING MITOCHONDRIAL DNA DISORDERS | UCL BUSINESS LTD (GB) | 2025-01-16 | — | — | US | claimed |
| EP-4433077-A1 | COMPOUNDS FOR TREATING MITOCHONDRIAL DNA DISORDERS | UCL Business Ltd (GB) | 2024-09-25 | — | — | EP | claimed |
| WO-2023089313-A1 | COMPOUNDS FOR TREATING MITOCHONDRIAL DNA DISORDERS | UCL BUSINESS LTD (GB) | 2023-05-25 | — | — | WO | claimed |
| CN-115177727-A | Linked gene inactivation biomarkers and targets for cancer therapy | 得克萨斯系统大学董事会 | 2022-10-14 | — | — | CN | claimed |
| US-20210379087-A1 | COMPOSITIONS FOR THE ELIMINATION OF SENESCENT CELLS | MEDIZINISCHE UNIVERSITÄT WIEN (AT) | 2021-12-09 | — | — | US | claimed |
| EP-3643305-A1 | COMPOSITIONS FOR THE ELIMINATION OF SENESCENT CELLS | Universität für Bodenkultur Wien (AT) | 2020-04-29 | — | — | EP | claimed |
| EP-2790738-B1 | COLLATERAL GENE INACTIVATION BIOMARKERS AND TARGETS FOR CANCER THERAPY | UNIV TEXAS (US) | 2019-08-14 | — | — | EP | claimed |
| US-20140378529-A1 | COLLATERAL GENE INACTIVATION BIOMARKERS AND TARGETS FOR CANCER THERAPY | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-12-25 | — | — | US | claimed |
| EP-2790738-A2 | COLLATERAL GENE INACTIVATION BIOMARKERS AND TARGETS FOR CANCER THERAPY | The Board of Regents of The University of Texas System (US) | 2014-10-22 | — | — | EP | claimed |
| WO-2013090732-A2 | COLLATERAL GENE INACTIVATION BIOMARKERS AND TARGETS FOR CANCER THERAPY | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-06-20 | — | — | WO | claimed |
| WO-2007072219-A2 | ALPHA ENOLASE-DIRECTED DIAGNOSTICS AND THERAPEUTICS FOR CANCER AND CHEMOTHERAPEUTIC DRUG RESISTANCE | AURELIUM BIOPHARMA INC. (US) | 2007-06-28 | — | — | WO | claimed |
| US-20070077583-A1 | Alpha enolase-directed diagnostics and therapeutics for cancer and chemotherapeutic drug resistance | AURELIUM BIOPHARMA, INC. (CA) | 2007-04-05 | — | — | US | claimed |
| CN-115502207-B | Hydroxamate-phosphonate/phosphinate compound and preparation method and application thereof | 南华大学 | 2025-04-18 | — | — | CN | disclosed |
| US-20250017950-A1 | COMPOUNDS FOR TREATING MITOCHONDRIAL DNA DISORDERS | UCL BUSINESS LTD (GB) | 2025-01-16 | — | — | US | disclosed |
| EP-4433077-A1 | COMPOUNDS FOR TREATING MITOCHONDRIAL DNA DISORDERS | UCL Business Ltd (GB) | 2024-09-25 | — | — | EP | disclosed |
| EP-4011890-B1 | ENOLASE INHIBITORS AND METHODS OF TREATMENT THEREWITH | UNIV TEXAS (US) | 2024-08-28 | — | — | EP | disclosed |
| US-20060116347-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | KIACTA SARL (CH) | 2006-06-01 | — | — | US | disclosed |
| US-6670399-B2 | Contacting a blood vessel wall cell with an A beta 40 inhibitor, such that cerebral amyloid angiopathy is inhibited | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2003-12-30 | — | — | US | disclosed |
| EP-1100487-A2 | COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH GLYCOSAMINOGLYCAN-ASSOCIATED MOLECULAR INTERACTIONS | Neurochem, Inc. (CA) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000006133-A2 | COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH GLYCOSAMINOGLYCAN-ASSOCIATED MOLECULAR INTERACTIONS | NEUROCHEM, INC. (CA) | 2000-02-10 | — | — | WO | disclosed |